Evaluation of Src Tyr419 as a predictive biomarker in a neoadjuvant trial using dasatinib in resectable malignant pleural mesothelioma.

7042 Background: Preclinical studies in malignant pleural mesothelioma (MPM) have shown that dasatinib, a multitargeted Src kinase/PDGFR inhibitor, has antitumor activity. We designed a novel bioma...